NLRP3 and atherosclerosis: It was also reported that NLRP3 inhibitors such as MCC950 applying to ApoE−/− mice after four weeks showed that although the mice body quality, blood sugar, very low-density lipoprotein cholesterol (VLDL-c), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c), triacylglycerol, and total cholesterols had no obvious changes, the area of atherosclerotic plaque decreased significantly, which in turn showed that MCC950 can inhibit the expression of NLRP3 for treatment of atherosclerosis [75].